Product description

Therapeutic Area: Alimentary tract & Metabolism
  • EU DMF available
  • US DMF no. 21149 avalable
  • CEP available

Indication: Repaglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces insulin secretion.


Read more

Specifications

Details C27H36N2O4
Categories Contract Services - Contract ServicesContract Manufacturing
Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Supplied from Poland
Measured In g; Kgs

More products from ZF Polpharma SA

View all our products (32)

Products from other suppliers